The Enterprise Value as of September 2024 (TTM) for uniQure N.V. (QURE) is 510.02M

According to uniQure N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 510.02M. This represents a change of 39.28% compared to the average of 366.17M of the last 4 quarters.

uniQure N.V. (QURE) Historical Enterprise Value (quarterly & annually)

How has QURE Enterprise Value performed in the past?

The mean historical Enterprise Value of uniQure N.V. over the last ten years is 734.06M. The current 510.02M Enterprise Value has changed 6.85% with respect to the historical average. Over the past ten years (40 quarters), QURE's Enterprise Value was at its highest in in the June 2019 quarter at 2.79B. The Enterprise Value was at its lowest in in the June 2016 quarter at 21.70M.

uniQure N.V. (QURE) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of uniQure N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

uniQure N.V. (QURE) Average Enterprise Value

How has QURE Enterprise Value performed in the past?

The current Enterprise Value of uniQure N.V. (QURE) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

uniQure N.V. (QURE) Enterprise Value vs. Peers

How is QURE’s Enterprise Value compared to its peers?

uniQure N.V.’s Enterprise Value is less than Rocket Pharmaceuticals, Inc. (1.73B), less than Rhythm Pharmaceuticals, Inc. (3.12B), greater than Solid Biosciences Inc. (220.06M), greater than MeiraGTx Holdings plc (312.67M), less than Terns Pharmaceuticals, Inc. (570.95M), greater than Amylyx Pharmaceuticals, Inc. (108.56M), greater than Acumen Pharmaceuticals, Inc. (112.86M), greater than Inozyme Pharma, Inc. (407.26M), greater than X4 Pharmaceuticals, Inc. (42.64M), less than Vaxcyte, Inc. (13.42B), greater than Larimar Therapeutics, Inc. (400.15M), less than Syndax Pharmaceuticals, Inc. (1.44B), less than Merus N.V. (2.81B), greater than Sutro Biopharma, Inc. (402.91M), less than Kiniksa Pharmaceuticals, Ltd. (1.70B), less than Day One Biopharmaceuticals, Inc. (956.75M), less than Structure Therapeutics Inc. (1.91B), less than Karuna Therapeutics, Inc. (12.43B), less than Phathom Pharmaceuticals, Inc. (1.52B), less than REGENXBIO Inc. (730.60M), less than Replimune Group, Inc. (638.93M), less than Avidity Biosciences, Inc. (4.32B), less than Protagonist Therapeutics, Inc. (2.38B),

Build a custom stock screener for uniQure N.V. (QURE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like uniQure N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

uniQure N.V. (QURE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like uniQure N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.